Tokushima University / Educator and Researcher Directory --- Yukishige, Sawaka

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Souichiro Sasa, Hiroaki Inoue, Misako Nakagawa, Hiroaki Toba, Masakazu Goto, Kazumasa Okumura, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Aya Nishisho, Naoki Hino, Miyuki Kanematsu, Yoshimi Bando, Hisanori Uehara, Akira Tangoku and Hiromitsu Takizawa : Long-term outcomes of S-1 combined with low-dose docetaxel as neoadjuvant chemotherapy (N-1 study, phase II trial) in patients with operable breast cancer, Clinical Breast Cancer, 24, 5, e350-e359, 2024. (Summary) We previously reported that S-1 and low-dose docetaxel (DOC) (N-1 study, phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) for patients with operable breast cancer. Herein, we analyzed the long-term outcomes and developed clinicopathological and molecular predictors of pathological complete response (pCR). Eighty-three patients received S-1 (40 mg/m orally on days 1-14) and DOC (40 mg/m intravenously on day 1) every 3 weeks for 4 to 8 cycles. Disease-free survival (DFS) and overall survival (OS) were analyzed for each population with a pCR status. To assess the relationship between pCR and clinicopathological factors such as tumor-infiltrating lymphocytes (TILs, 1+ <10%, 2+ 10%-50%, and 3+ >50%) and nuclear grade (NG), microarray was used to compare the microRNA profiles of the pCR and non-pCR groups using core needle biopsy specimens. With a median follow-up duration of 99.0 (range, 9.0-129.0) months, the 5-year DFS and OS rates were 80.7% and 90.9%, respectively. The 5-year OS rate of the pCR group was significantly better than that of the non-pCR group (100% vs. 86.2%, p = .0176). Specifically, in triple-negative patients, the difference was significant (100% vs. 60.0%, p = .0224). Multivariate analysis revealed that high TILs (≥2-3+) and NG 2-3 independently predicted pCR. Microarray data revealed that 3 miRNAs (miR-215-5p, miR-196a-5p, and miR-196b-5p) were significantly upregulated in the pCR group. Our NAC regimen achieved favorable long-term outcomes and significantly improved OS in the pCR group. High TILs, NG 2-3, and some miRNAs may be predictors of pCR. (Keyword) Humans / Female / Docetaxel / Neoadjuvant Therapy / Oxonic Acid / Antineoplastic Combined Chemotherapy Protocols / Middle Aged / Tegafur / Breast Neoplasms / Drug Combinations / Adult / Aged / Lymphocytes, Tumor-Infiltrating / Follow-Up Studies / Taxoids / Disease-Free Survival / Treatment Outcome / Prognosis / MicroRNAs (Tokushima University Institutional Repository) ● Metadata: 2011475 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clbc.2024.02.014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38462397 ● Search Scopus @ Elsevier (PMID): 38462397 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clbc.2024.02.014 (Tokushima University Institutional Repository: 2011475, DOI: 10.1016/j.clbc.2024.02.014, PubMed: 38462397)
2.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroyuki Morino, 吉田友紀子, 宮本容子 and Hiromitsu Takizawa : BRCA遺伝学的検査の結果inconclusiveとなった3例, Journal of Hereditary Tumors, 24, 2, 147-152, 2024.
3.	Tomohiro Inui, Hiroaki Inoue, 磯村祐太, Sawaka Yukishige, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : A case of severe interstitial lung disease developed during administration of abemaciclib but successfully rescued, Shikoku Acta Medica, 80, 3,4, 121-124, 2024. (Keyword) abemaciclib / cyclin-dependent kinase 4 and 6 inhibitor / breast cancer / interstitial lung disease (Tokushima University Institutional Repository) ● Metadata: 2012480 (Link to Publication Site) ● Publication site (DOI): 10.57444/shikokuactamedica.80.3.4_121 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390583469490453632 ● Search Scopus @ Elsevier (DOI): 10.57444/shikokuactamedica.80.3.4_121 (Tokushima University Institutional Repository: 2012480, DOI: 10.57444/shikokuactamedica.80.3.4_121, CiNii: 1390583469490453632)
4.	Naoki Miyamoto, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Naoki Hino, Aya Nishisho, Sawaka Yukishige, Taeko Kawanaka, Hiromitsu Takizawa and Akira Tangoku : Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients, Clinical Breast Cancer, 23, 3, e68-e76, 2023. (Summary) Some reports have shown that absolute lymphocyte count (ALC) is associated with prognosis in breast cancer; however, the impact of ALC changes remains unclear. This study aimed to investigate the relationship between ALC changes during neoadjuvant chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer patients and disease prognosis. This retrospective cohort study January 2010 to September 2020) included patients diagnosed with HER2-positive breast cancer and treated with trastuzumab-based neoadjuvant chemotherapy. The ALC ratio was defined as the ALC value after administration of the anti-HER2 drug divided by the ALC value before administration. The optimal ALC ratio cut-off value was identified using the receiver operating characteristic curve analysis and Youden's index. The relationship between the ALC ratio and disease-free survival was assessed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Data from a total of 100 HER2-positive breast cancer patients were analyzed. The cut-off value of the ALC ratio was set as 1.142. The median follow-up period was 52.0 (range: 5.1-123.7) months. The 5-year disease-free survival rates were 88.4% and 60.9% in the high-and low-ALC ratio groups, respectively, and were significantly higher in the high-ALC ratio group (p = .0031). The ALC ratio was an independent prognostic factor in multivariate Cox proportional hazards analysis (p = .0032). HER2-positive breast cancer patients with a higher ALC ratio during trastuzumab-based neoadjuvant chemotherapy may have a better prognosis than their counterparts. (Keyword) Humans / female / Breast Neoplasms / Neoadjuvant Therapy / Retrospective Studies / Receptor, ErbB-2 / Prognosis / Trastuzumab / Disease-Free Survival / Lymphocyte Count / Antineoplastic Combined Chemotherapy Protocols (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clbc.2023.01.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36682907 ● Summary page in Scopus @ Elsevier: 2-s2.0-85147563272 (DOI: 10.1016/j.clbc.2023.01.005, PubMed: 36682907, Elsevier: Scopus)
5.	Masami Morimoto, Sawaka Yukishige, 池内真由美, Misako Nakagawa, Hirokazu Takechi, Hiroaki Toba and Akira Tangoku : Case reports : A case of advanced breast cancer with spinal palsy due to cervical bone metastasis who was improved a quality of life by emergent multidisciplinary oncological salvage, Shikoku Acta Medica, 74, 3,4, 119-124, 2018. (Summary) A 60s female complained of right thigh pain caused by bone metastasis from advanced breast cancer. She was introduced to our ward for systemic therapy with palliative radiation to painful osteolytic lesion in the right femur. She suddenly complained of serious pain and motility disturbance in the right upper-extremity two days after her admission. Magnetic resonance imaging(MRI)suggested bone metastasis in the 3rd cervical vertebra which compressed spinal cord. We discussed about an optimal treatment with the orthopedic surgeon and the radiation therapeutic physician, and laminectomy was scheduled promptly. She also had a right femur fracture a day before her planed laminectomy, so she underwent osteosynthesis of the femur together with laminectomy of the cervical vertebra. She also received the irradiation to the 3rd cervical vertebra and the shaft of right femur. She became able to eat with a spoon by herself and her activity of daily living(ADL)have fully recovered by daily rehabilitation. She is receiving chemotherapy in our out-patient clinic now. We recognized that an emergent oncological treatment for the spinal decompression by the bone metastasis could improve the patients' quality of life(QOL)to avoid the permanent paralysis and also their prognoses. (Keyword) spinal decompression / breast cancer / bone metastasis (Tokushima University Institutional Repository) ● Metadata: 2005455 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050585658875345024 (Tokushima University Institutional Repository: 2005455, CiNii: 1050585658875345024)
6.	Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, G Julie Ledford, Saburo Sone and Yasuhiko Nishioka : Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages., The American Journal of Pathology, 182, 5, 1843-1853, 2013. (Summary) Surfactant protein A (SP-A) is a large multimeric protein found in the lungs. In addition to its immunoregulatory function in infectious respiratory diseases, SP-A is also used as a marker of lung adenocarcinoma. Despite the finding that SP-A expression levels in cancer cells has a relationship with patient prognosis, the function of SP-A in lung cancer progression is unknown. We investigated the role of SP-A in lung cancer progression by introducing the SP-A gene into human lung adenocarcinoma cell lines. SP-A gene transduction suppressed the progression of tumor in subcutaneous xenograft or lung metastasis mouse models. Immunohistochemical analysis showed that the number of M1 antitumor tumor-associated macrophages (TAMs) was increased and the number of M2 tumor-promoting TAMs was not changed in the tumor tissue produced by SP-A-expressing cells. In addition, natural killer (NK) cells were also increased and activated in the SP-A-expressing tumor. Moreover, SP-A did not inhibit tumor progression in mice depleted of NK cells. Taking into account that SP-A did not directly activate NK cells, these results suggest that SP-A inhibited lung cancer progression by recruiting and activating NK cells via controlling the polarization of TAMs. (Tokushima University Institutional Repository) ● Metadata: 2002276 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ajpath.2013.01.030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23499372 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876522439 (Tokushima University Institutional Repository: 2002276, DOI: 10.1016/j.ajpath.2013.01.030, PubMed: 23499372, Elsevier: Scopus)
7.	Trung The Van, Masaki Hanibuchi, Hisatsugu Goto, Takuya Kuramoto, Sawaka Yukishige, Souji Kakiuchi, Seidai Sato, Satoshi Sakaguchi, Le Tan Dat, Yasuhiko Nishioka, Shin-ichi Akiyama and Saburo Sone : SU6668, a multiple tyrosine kinase inhibitor, inhibits the progression of human malignant pleural mesothelioma in an orthotopic model, Respirology, 17, 6, 984-990, 2012. (Summary) Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the mesothelium with high chemotherapeutic resistance. In this study, the preclinical therapeutic activity of the multiple tyrosine kinase inhibitor, SU6668, against MPM was examined. Two human MPM cell lines with different pro-angiogenic cytokine expression, Y-MESO-14 cells that express high levels of vascular endothelial growth factor (VEGF) and MSTO-211H cells that express high levels of basic fibroblast growth factor (bFGF), were orthotopically inoculated into the thoracic cavities of mice with severe combined immunodeficiency. The mice with MPM were treated or not treated with SU6668 (200 mg/kg/day). SU6668 abrogated the proliferation of endothelial cells stimulated by VEGF or bFGF, but did not directly affect the growth of human MPM cells in vitro. In this orthotopic implantation model, treatment with SU6668 effectively reduced tumour weight and pleural effusion volumes, in association with inhibition of the growth of tumour vasculature. More importantly, treatment with SU6668 significantly prolonged survival time in mice with MPM. These findings suggest that SU6668 has a promising therapeutic effect on the progression of MPM in vivo through its anti-angiogenic effects. (Keyword) Animals / Antineoplastic Agents / Cell Line, Tumor / Cell Proliferation / Fibroblast Growth Factor 2 / Humans / Indoles / male / Mesothelioma / Mice / Mice, SCID / Neovascularization, Pathologic / Pleural Effusion, Malignant / Pleural Neoplasms / Protein Kinase Inhibitors / Pyrroles / vascular endothelial growth factor / Xenograft Model Antitumor Assays (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1440-1843.2012.02193.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22574723 ● Summary page in Scopus @ Elsevier: 2-s2.0-84864420426 (DOI: 10.1111/j.1440-1843.2012.02193.x, PubMed: 22574723, Elsevier: Scopus)

Proceeding of International Conference:

1.	Sawaka Yukishige, Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone and Yasuhiko Nishioka : Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization., Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, Maui, Feb. 2013.
2.	Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G Ledford, Saburo Sone and Yasuhiko Nishioka : Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response, Joint Meeting to Seoul National University, Seoul, Dec. 2012.

Proceeding of Domestic Conference:

1.	Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroyuki Morino, 吉田友紀子 (名), 宮本容子 (名), Yoshie Imai and Hiromitsu Takizawa : 当院におけるHBOC血縁者に対するBRCA遺伝学的検査実施状況, 第31回日本遺伝性腫瘍学会学術集会, Jun. 2025.
2.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 馬場彩花, 竹原恵美, Sawaka Yukishige, 竹内大平, 藤本啓介, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Souichiro Sasa, Atsushi Morishita, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : 進行食道癌に対する術前化学療法としてのweekly docetaxel plus low-dose cisplatin and 5-FU(DFP)療法の有効性と安全性の検討, 第125回日本外科学会定期学術集会, Apr. 2025.
3.	阿部祐也, Souichiro Sasa, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Mariko Aoyama, Atsushi Morishita, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 乳房石灰化が特異的な経過を示した乳癌術後ホルモン療法中の1症例, 第34回日本乳癌検診学会学術総会, Nov. 2024.
4.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Kazumasa Okumura, Masakazu Goto, Yoshimi Bando and Hiromitsu Takizawa : 精査機関である当院におけるPPV3の検討, 第34回日本乳癌検診学会学術総会, Nov. 2024.
5.	Hiroshi Miyamoto, Ayuka Mineda, Sawaka Yukishige, Soichiroh Sasa, Kei Daizumoto, Tomoya Fukawa, Yasuyuki Okada, Yasuhiro Mitsui, Koichi Okamoto, Yasushi Sato, Hiroyuki Morino and Tetsuji Takayama : Management of patients with presumed germline pathogenic variant from comprehensive genomic profiling tests., 日本人類遺伝学会第69回大会, Oct. 2024.
6.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroyuki Morino, 吉田友紀子, 宮本容子, Yoshie Imai and Hiromitsu Takizawa : Two cases of surveillance using DWIBS in Li-Fraumeni syndrome, 日本人類遺伝学会第69回大会, Oct. 2024.
7.	阿部祐也, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多職種による介入が効果的であった出血を伴う局所進行乳癌の1例, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
8.	藤稿智宏, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Hiroaki Toba, Masakazu Goto, 広瀬敏幸, Hisanori Uehara and Hiromitsu Takizawa : 乳房超音波検査にてhaloを伴い乳癌が疑われたadenosisの1例, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
9.	馬場彩花, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Atsushi Morishita, Naoki Miyamoto, 藤本啓介, 竹原恵美, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多発肺転移を有するホルモン陽性乳癌に対しエチニルエストラジオールを投与し長期奏功を得た一例, 第21回日本乳癌学会中国四国地方会, Sep. 2024.
10.	Yoshie Imai, Hiroaki Inoue, 宮本容子, 吉田友紀子, Hiroyuki Morino, 湊沙希, Souichiro Sasa, Sawaka Yukishige and Hiroshi Miyamoto : BRCA2 variant of uncertain significanceと診断された乳癌症例の血縁者に対するサーベイランスの一考, 第31回日本がん予防学会総会, Sep. 2024.
11.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 馬場彩花, 竹原恵美, Sawaka Yukishige, 竹内大平, 藤本啓介, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita and Hiromitsu Takizawa : 当院における食道癌手術の定型化への取り組みと術後短期成績について, 第99回中国四国外科学会総会/第29回中国四国内視鏡外科研究会, Sep. 2024.
12.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 術前化学療法後に手術を含めた集学的治療を拒否したHER2陽性局所進行乳癌の1例, 第32回日本乳癌学会学術総会, Jul. 2024.
13.	Mariko Aoyama, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 術前診断が困難だった乳腺粘液癌肝転移の1例, 第32回日本乳癌学会学術総会, Jul. 2024.
14.	Tomohiro Inui, Hiroaki Inoue, 細川暉雄, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当院におけるトラスツズマブデルクステカン投与例の検討, 第32回日本乳癌学会学術総会, Jul. 2024.
15.	細川暉雄, Hiroaki Inoue, Tomohiro Inui, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : ペムブロリズマブ投与中に下垂体機能低下を認めたトリプルネガティブ乳癌の1例, 第32回日本乳癌学会学術総会, Jul. 2024.
16.	Souichiro Sasa, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Mariko Aoyama, 細川暉雄, Atsushi Morishita, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当院における周術期トリプルネガティブ乳癌に対するペムブロリズマブの使用経験, 第32回日本乳癌学会学術総会, Jul. 2024.
17.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Naoki Miyamoto, Atsushi Morishita, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : CDK4/6阻害剤における有害事象とCARGスコアについての検討, 第32回日本乳癌学会学術総会, Jul. 2024.
18.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : エリブリン投与中の病勢進行形式と末梢血総リンパ球数の関係について, 第32回日本乳癌学会学術総会, Jul. 2024.
19.	Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroyuki Morino, 吉田友紀子, 宮本容子, Yoshie Imai, Masakazu Goto and Hiromitsu Takizawa : 当院乳癌患者におけるBRCA遺伝学的検査の現状, 第30回日本遺伝性腫瘍学会学術集会, May 2024.
20.	杉本花奈乃, Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Sawaka Yukishige, Mariko Aoyama, Hiroaki Toba, Masakazu Goto, Yoshimi Bando and Hiromitsu Takizawa : 乳頭の硬結で発見された浸潤性小葉癌の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
21.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Takeshi Oya, Yoshimi Bando, Masakazu Goto and Hiromitsu Takizawa : 乳腺原発神経内分泌腫瘍の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
22.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba, Takashi Kawanaka and Hiromitsu Takizawa : 顔面のしびれを契機に発見された頭蓋底骨転移に対し放射線治療が有効であった1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
23.	細川暉雄, Tomohiro Inui, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba and Hiromitsu Takizawa : 有害事象マネジメントにより術前ペムブロリズマブ投与を継続しpCRの診断を得たトリプルネガティブ乳癌の1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
24.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 高Ca血症のコントロールに難渋した乳癌多発骨転移の1例, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
25.	Satoshi Fujiwara, Sawaka Yukishige, Taihei Takeuchi, 髙杉遥, Hiroyuki Sumitomo, Atsushi Morishita, Seiya Inoue, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 食道癌手術における胃管作成に対する術式の検討, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
26.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Naoki Miyamoto, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
27.	Masakazu Goto, 井﨑富由実, Sawaka Yukishige, Taihei Takeuchi, Hiroyuki Sumitomo, Satoshi Fujiwara, Seiya Inoue and Hiromitsu Takizawa : 当科における高齢者食道癌患者に対する治療戦略と予後について, 第78回日本消化器外科学会総会, Jul. 2023.
28.	Masakazu Goto, 井﨑富由実, Sawaka Yukishige, Taihei Takeuchi, Hiroyuki Sumitomo, Mariko Aoyama, Satoshi Fujiwara, Seiya Inoue, Hiroaki Toba and Hiromitsu Takizawa : 当院における高齢者食道癌患者に対する治療と予後について, 第77回日本食道学会学術集会, Jun. 2023.
29.	Tomohiro Inui, Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 当院における肉芽腫性乳腺炎治療の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
30.	Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba, Hiromitsu Takizawa, 甫喜本憲弘 and 頼田顕辞 : 局所皮弁による再建を行った腋窩副乳癌の1例, 第31回日本乳癌学会学術総会, Jun. 2023.
31.	Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
32.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Morino, 吉田友紀子, 宮本容子 and Hiromitsu Takizawa : BRCA遺伝学的検査の結果inconclusiveとなった3例, 第29回日本遺伝性腫瘍学会学術集会, Jun. 2023.
33.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Sawaka Yukishige, Kazumasa Okumura, Hirokazu Takechi and Akira Tangoku : HER2およびEGFRの発現から見た食道癌の治療戦略(第二報), 第72回日本食道学会学術集会, Jun. 2018.
34.	Masami Morimoto, Sawaka Yukishige, Mayumi Ikeuchi, Misako Nakagawa, Hiroaki Toba, Hirokazu Takechi and Akira Tangoku : HER2陰性ホルモン受容体陽性進行・再発乳癌に対するパクリタキセル/ベバシズマブ療法の治療成績, 第26回日本乳癌学会学術総会, May 2018.
35.	Hirokazu Takechi, Masami Morimoto, Misako Nakagawa, Hiroaki Toba, Sawaka Yukishige, Mayumi Ikeuchi, Kazumasa Okumura, Takahiro Yoshida and Akira Tangoku : 悪性リンパ腫経過観察中に実施した腋窩リンパ節生検で発見した乳癌の1例, 第26回日本乳癌学会学術総会, May 2018.
36.	Mayumi Ikeuchi, Sawaka Yukishige, Masami Morimoto, Misako Nakagawa, Kazumasa Okumura, Hirokazu Takechi, Hiroaki Toba and Akira Tangoku : 胸壁浸潤を伴う局所再発に対して切除を行った超高齢者乳癌の2例, 第26回日本乳癌学会学術総会, May 2018.
37.	Sawaka Yukishige, Mayumi Ikeuchi, Masami Morimoto, Misako Nakagawa, Hiroaki Toba, Hirokazu Takechi and Akira Tangoku : 乳腺基質産生癌(matrix-producing carcinoma)の3例, 第26回日本乳癌学会学術総会, May 2018.
38.	Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Seiya Inoue, Kazumasa Okumura, Sawaka Yukishige, Hiroaki Toba and Akira Tangoku : T4食道癌に対する集学的治療と課題, 第118回日本外科学会定期学術集会, Apr. 2018.
39.	青山万理子, Mitsuteru Yoshida, Sawaka Yukishige, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa, Kazuya Kondo and Akira Tangoku : 後縦隔ミュラー管嚢胞の1例, 第79回日本臨床外科学会総会, Nov. 2017.
40.	Sawaka Yukishige, Yukikiyo Kawakami, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Hiroaki Toba, Mitsuteru Yoshida, Hiromitsu Takizawa, Kazuya Kondo and Akira Tangoku : Minute pulmonary meningothelial like nodulesの3例, 第79回日本臨床外科学会総会, Nov. 2017.
41.	Hiroaki Toba, Sawaka Yukishige, 池内真由美, 森本雅美, Misako Nakagawa, Kazumasa Okumura, Hirokazu Takechi and Akira Tangoku : 《一般口演》乳癌治療経過中に発見された肺腫瘤の診断, 第27回日本乳癌検診学会学術総会, Nov. 2017.
42.	森本雅美, Hirokazu Takechi, Sawaka Yukishige, 池内真由美, Misako Nakagawa and Akira Tangoku : 検診で指摘され得なかった腋窩副乳癌の1例, 第27回日本乳癌検診学会学術総会, Nov. 2017.
43.	Misako Nakagawa, Sawaka Yukishige, 池内真由美, 森本雅美, Kazumasa Okumura, Hirokazu Takechi, Hiroaki Toba and Akira Tangoku : 《一般口演》当院における検診発見乳癌-自覚症状の有無の観点から-, 第27回日本乳癌検診学会学術総会, Nov. 2017.
44.	森本雅美, Hirokazu Takechi, Sawaka Yukishige, 池内真由美, Misako Nakagawa and Akira Tangoku : 《一般口演》当院におけるステレオガイド下マンモトーム生検の検討, 第27回日本乳癌検診学会学術総会, Nov. 2017.
45.	Hirokazu Takechi, Sawaka Yukishige, 池内真由美, 森本雅美, Misako Nakagawa, Kazumasa Okumura, Hiroaki Toba and Akira Tangoku : 《一般口演》悪性リンパ腫の経過観察中に実施した腋窩リンパ節生検で発見した乳癌の1例, 第27回日本乳癌検診学会学術総会, Nov. 2017.
46.	Sawaka Yukishige, 森本雅美, Hirokazu Takechi, 池内真由美, Misako Nakagawa, Hiroaki Toba and Akira Tangoku : 《一般口演》妊娠中に診断された乳腺癌肉腫の1例, 第27回日本乳癌検診学会学術総会, Nov. 2017.
47.	池内真由美, 森本雅美, Hirokazu Takechi, Sawaka Yukishige, Misako Nakagawa and Akira Tangoku : 《一般口演》初診時の針生検で悪性所見を認めず6ヶ月後にPaget病と診断された1例, 第27回日本乳癌検診学会学術総会, Nov. 2017.
48.	Hirokazu Takechi, 山尾雅美, 平田有紀奈, 松本真依, 西尾進, Sawaka Yukishige, 池内真由美, 森本雅美, Misako Nakagawa, Kazumasa Okumura, Hiroaki Toba and Akira Tangoku : 《一般口演》超音波検査センターとの連携で確定診断できた乳癌3例, 第27回日本乳癌検診学会学術総会, Nov. 2017.
49.	森本雅美, Sawaka Yukishige, 池内真由美, Hirokazu Takechi, Misako Nakagawa, Hiroaki Toba and Akira Tangoku : 当院におけるHER2陽性転移再発乳癌に対するトラスツズマブエムタンシンの治療成績, 第55回日本癌治療学会学術集会, Oct. 2017.
50.	Hirokazu Takechi, Sawaka Yukishige, 青山万理子, 池内真由美, 森本雅美, Seiya Inoue, Masakazu Goto, Takeshi Nishino, Misako Nakagawa, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : 乳癌治療における近藤誠理論の問題点を実感した1例, 第14回日本乳癌学会中国四国地方会, Sep. 2017.
51.	Sawaka Yukishige, 森本雅美, Hirokazu Takechi, Misako Nakagawa, Hiroaki Toba and Akira Tangoku : 輸血せずに集学的治療により止血せしめた薬剤抵抗性血管浸潤進行副乳癌の1例, 第14回日本乳癌学会中国四国地方会, Sep. 2017.
52.	森本雅美, Sawaka Yukishige, 池内真由美, Hirokazu Takechi, Misako Nakagawa, Hiroaki Toba and Akira Tangoku : 形成外科との協働による乳房切除後再建症例の検討, 第14回日本乳癌学会中国四国地方会, Sep. 2017.
53.	池内真由美, 森本雅美, Hirokazu Takechi, Sawaka Yukishige, Misako Nakagawa and Akira Tangoku : 《優秀演題セッション》乳癌術後補助化学療法中に白質脳症をきたした1例, 第14回日本乳癌学会中国四国地方会, Sep. 2017.
54.	Sawaka Yukishige, 森本雅美, Hirokazu Takechi, Misako Nakagawa, Hiroaki Toba, Akira Tangoku, Seiji Iwamoto, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 輸血せずに集学的治療により止血せしめた薬剤抵抗性血管浸潤進行副乳癌の1例, 第42回日本外科系連合学会学術集会, Jun. 2017.
55.	Sawaka Yukishige, Kenya Kusunose, 瀬野弘光, 西條良仁, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 成人期に心不全症状を契機に発見された左室緻密化障害の一例, 第109回日本循環器学会四国地方会, Dec. 2016.
56.	Sawaka Yukishige, Hirokazu Takechi, 森本雅美, Misako Nakagawa, Kazumasa Okumura, Hiroaki Toba, 西岡康平, 藤本啓介, 宮本直輝, 青山万理子, Seiya Inoue, Takeshi Nishino, Takahiro Yoshida and Akira Tangoku : 地域連携を依頼しながら症状緩和に努めた乳腺悪性葉状腫瘍の1例, 第78回日本臨床外科学会総会, Nov. 2016.
57.	Sawaka Yukishige, 乾友浩, 髙杉遥, 森本雅美, Misako Nakagawa, Hirokazu Takechi, Hiroaki Toba, Takahiro Yoshida, Yukiko Tadokoro and Akira Tangoku : 乳腺腺様嚢胞癌の2例, 第12回日本乳癌学会中国四国地方会, Sep. 2015.

Et cetera, Workshop:

1.	阿部祐也, Hiroaki Inoue, Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多職種による介入が効果的であった局所進行乳癌の1例, 第8回徳島外科医会, Feb. 2025.
2.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 髙杉遥, 細川暉雄, Sawaka Yukishige, Taihei Takeuchi, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Souichiro Sasa, Atsushi Morishita, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : 当院における腹臥位胸腔鏡下食道亜全摘術の術後短期成績について, 第36回四国内視鏡外科研究会, Mar. 2024.
3.	住友弘幸, Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 井﨑富由実, Sawaka Yukishige, 竹内大平, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Souichiro Sasa, 三崎万理子, Hiroaki Inoue, Mika Takashima, Naoya Kawakita, Kazumasa Okumura, Hiroaki Toba and Hiromitsu Takizawa : 食道癌術後，再建胃管穿孔による右膿胸を生じた1例, 第6回徳島外科医会, Feb. 2023.
4.	Satoshi Fujiwara, 井﨑富由実, Sawaka Yukishige, 竹内大平, Hiroyuki Sumitomo, Seiya Inoue, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 食道癌手術における胃管作成に対する術式の検討, 第43回四国食道疾患研究会学術講演会, Jan. 2023.
5.	Seiya Inoue, 井﨑富由実, Sawaka Yukishige, 竹内大平, Hiroyuki Sumitomo, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 術後補助療法としてのNivolumabの可能性, 第43回四国食道疾患研究会学術講演会, Jan. 2023.
6.	井﨑富由実, Masakazu Goto, Sawaka Yukishige, 竹内大平, Tomohiro Inui, Hiroyuki Sumitomo, Satoshi Fujiwara, Seiya Inoue, Hiroaki Toba and Hiromitsu Takizawa : 食道蠕動運動障害を伴う横隔膜上食道憩室に対して腹腔鏡下手術を施行した1例, 第43回四国食道疾患研究会学術講演会, Jan. 2023.
7.	竹内大平, Seiya Inoue, 井﨑富由実, Sawaka Yukishige, Hiroyuki Sumitomo, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 食道癌根治術後に急激な経過を辿った緑膿菌肺炎の一例, 第43回四国食道疾患研究会学術講演会, Jan. 2023.
8.	Takeshi Nishino, Takahiro Yoshida, Masakazu Goto, Seiya Inoue, 青山万理子, Sawaka Yukishige, 森本雅美, Hirokazu Takechi and Akira Tangoku : 縦隔鏡下食道癌根治術を目指したラーニングステップとしての縦隔鏡・胸腔鏡ハイブリッド手術, 第38回四国食道疾患研究会, Feb. 2018.
9.	Masakazu Goto, Takahiro Yoshida, Takeshi Nishino, Seiya Inoue, 青山万理子, Sawaka Yukishige, 森本雅美, Hirokazu Takechi and Akira Tangoku : 縦隔鏡下食道切除術における経裂孔的アプローチに必要な解剖, 第38回四国食道疾患研究会, Feb. 2018.
10.	Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Seiya Inoue, 青山万理子, Sawaka Yukishige, 森本雅美, Hirokazu Takechi and Akira Tangoku : CTリンパ管造影を用いた表在型食道癌におけるリンパ節転移診断と治療成績, 第38回四国食道疾患研究会, Feb. 2018.
11.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, 青山万理子, Sawaka Yukishige, 森本雅美, Hirokazu Takechi and Akira Tangoku : 食道癌におけるEGFR, HER-2発現の意義, 第38回四国食道疾患研究会, Feb. 2018.
12.	Hirokazu Takechi, Sawaka Yukishige, 池内真由美, 森本雅美, Misako Nakagawa, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : 高齢男性に発症した乳腺筋線維芽細胞腫の1例, 第24回日本乳腺疾患研究会, Feb. 2018.
13.	Sawaka Yukishige, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Seiya Inoue, Akira Tangoku, Hisanori Uehara and Akiko Yoneda : 食道アカラシアに合併した食道扁平上皮癌に対する食道亜全摘術の1例, 2017年度徳島外科医会, Feb. 2018.
14.	Sawaka Yukishige, Hiroaki Toba, Yukikiyo Kawakami, Kazuya Kondo, 河北直也, Mitsuhiro Tsuboi, Koichiro Kajiura, Hiromitsu Takizawa, Shoji Sakiyama and Akira Tangoku : 肺犬糸状虫症の1切除例, 第251回徳島医学会学術集会, Aug. 2015.

Designated Assistant Professor : Yukishige, Sawaka

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop: